Developing the First-in-Class Topical “Soft” BET Inhibitor for the Treatment of Non-Segmental Vitiligo
Time: 11:30 am
day: Day Two Clinical Track AM
Details:
- Interrogating the role of the bromodomain and end terminal family of proteins and reviewing in vivo and ex vivo non-clinical efficacy of VYN201
- Advancing the application of a soft drug and target tissue strategy to focus on-target effect and mitigate toxicity
- Reviewing a Phase 1a/b study in healthy volunteers and patients with non-segmental vitiligo to inform future advances in using BET inhibitors
